cookie

Translate

venerdì 31 marzo 2017

6 ways new federal bills would protect California cannabis consumers, businesses

Hemant Lata, left, and Suman Chandra work at a federally-approved medical marijuana facility at the University of Mississippi in Oxford in 2014. (File photo by Lance Murphey, The New York Times)

giovedì 23 marzo 2017

Coltivare cannabis per rilanciare lo sviluppo economico italiano

Il 2015 è stato l' anno di Expo a Milano. E' stato presentato un interessante progetto di sviluppo dell'agricoltura sostenibile, ad impatto 0, utilizzando risorse rinnovabili, evitando lo sfruttamento del suolo: Skyland.

Pensavano di costruirlo a Milano per Expo, così come era stata costruita la Torre Eiffel per l' esposizione universale a Parigi del 1889. Ragioni economiche hanno, ovviamente, evitato la costruzione di un'opera ingegnieristica che potrebbe rilanciare l'economia italiana. Perchè? Perchè la costruzione di grattacieli di 30 piani e la vendita di questi "innovativi" impianti, genererebbe un indotto del quale potrebbe avvantaggiarsi tutta l'economia italiana.


Aimè l'economia oggi va male e sognare che l'Italia possa tornare economicamente la potenza che è stata durante gli anni 50 sembrerebbe un sogno. 


Se non fosse che proprio la coltivazione della cannabis potrebbe permettere la realizzazione a costo zero di Skyland e lanciare una nuova politica industriale basata sul lancio di una impiantistica agroindustriale per paesi in via di sviluppo. Vendere tecnologia in cambio di quello che è più utile per la nostra nazione.


Ma come sarebbe possibile tutto questo? 


Skyland prevede la realizzazione di un'area coltivabile di 100.000 mq. La destinazione di 33.000 mq a coltivazione di cannabis medica potrebbe generare circa 400 milioni di euro l'anno e ricavi stimabili attorno ai 300 milioni annui. Con questi numeri la costruzione di un grattacielo "verde" non solo risulta economicamente sostenibile, ma i ritorni dall'investimento nell'infrastruttura sarebbe certi e veloci. Resterebbero altri 67.000 mq per la coltivazione a km zero di vegetali, la realizzazione di spazi per la vendita al dettagli a km zero di prodotti biologici senza l'uso di pesticidi (dati dalla coltivazione indoor) dal produttore al consumatore con risparmi notevoli per quest'ultimo che eviterebbe la GDO. I raccolti sarebbero certi e non sottomessi alle bizze del tempo garantendo prezzi stabili per i consumatori.


L'indotto generato da un piano industriale nazionale finalizzato al lancio di questa nuova tecnologia potrebbe dare respiro e nuova linfa a settori che vanno dalla edilizia (per la realizzazione della struttura), all'elettronica, all'idraulica, all'energetica, solo per citarne alcuni.


Ma oggi tutto è fermo. La politica sta frenando lo sviluppo italiano. La cannabis è coltivabile solo sulla carta, tramite una autorizzazione ministeriale che, se chiesta, non verrà mai concessa. 


Una minoranza ottusa impedisce il rilancio italiano, credendo ancora che parlare di cannabis significhi parlare di "droga" e pensando ancora che questo gli porterà voti.


E' un peccato che l'italia non abbia la possibilità di realizzare una politica industriale nazionale e che, ancora oggi, parlare di cannabis si riduca ad una "allucinazione" proibizionista.



sabato 18 marzo 2017

Cannabis Science Inc (OTCMKTS:CBIS) Gets Delivery Announcements For Initial Greenhouse Orders

By Elizabeth Jackson / in Marijuana / on Tuesday, 14 Mar 2017 03:06 AM 


Cannabis Science Inc (OTCMKTS:CBIS) a U.S. firm specializing in the advancement of cannabis-based drugs announced the anticipated delivery of its first pre-designed greenhouses with tracking and reporting protocols available for delivery this week for California and Nevada operations.
Time to enhance efficiencies

Dr. Allen Herman, the CMO, said that having control over Cannabis Science supply chain will increase efficiencies, counting the cost and time required to have processed items readily available for development into formulations. Observational studies will be soon launched for specific cannabinoid combinations for certain critical ailments. The need is to grow a variety of cannabinoid combinations for testing and formulations.

Moreover, each formulation will target a certain critical ailment and work using a specific delivery mode. It will sport the potency to achieve maximum positive results in subject usage. The company has received multiple emails inquiring about the clinical research timing and the availability of cure options. These inquiries are about the pain management, peripheral neuropathies, COPD and cancer.

All inquiries are entered into in-house database and they will be responding to all as each targeted observational trial officially begins. The trials will comprise some of the more than 500 cannabinoids isolated and noted from Cannabis sativa. These cannabinoids come under the chemical class of terpenophenolics, and 85 out of these 500 cannabinoids have been uniquely recognized in cannabis.

Common crop cannabinoids include tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene and cannabinol. The THC pharmacology has been widely assessed, and it is regarded as the prime psychoactive constituent of cannabis. Their in-house database will mark the foundation of PCOR for a variety of critical disorders.

Later, Cannabis Science will develop protocols for their international consortium of South African, European and United States universities and research institutions. It will support research conventions for animal studies and clinical trials for numerous serious clinical ailments concurrently.

lunedì 13 marzo 2017


Dr. Stuart Titus, CEO Of Medical Marijuana Inc., Talks About Running "A Company Of Firsts"

By Nick Hilden | Mar 7, 2017 | C-Suite, Cannabis Investing


Dr. Stuart Titus is the CEO at Medical Marijuana Inc. (OTC: MJNA, OTCMKTS: MJNA), which has been pushing the boundaries of the medicinal space for nearly a decade. The company produces a range of hemp CBD oil products.

For starters, what makes your company different from others in the cannabis space?
We are a company of firsts – we were the first public company in the space in March 2009, the first to develop a natural botanical hemp-based CBD nutritional supplement, the first to legalize a cannabis-based product into a Latin American country (Brazil, April 2014), the first to legalize a cannabis based product into Mexico, and the first to develop a cannabis based product that qualifies for World Anti-Doping Standards.

How did you get into the cannabis space?
I entered this space via my physiotherapy career – I saw numerous athletes using cannabis to relieve pain, control inflammation, or just to help “get into the zone”. So I started attending medical cannabis symposiums to see if there was any real science behind this, and my eyes were opened to a new world of cannabis-based therapeutics.

Walk us through a normal day.
It starts with meetings with sales associates followed by meetings with management on product innovation, formulation. Next, media requests and developing presentation materials, then reading up on the latest clinical studies. From there I check the performance of our stock, our pharma partner’s stock, and other stocks in the space. Then I look at our international business, look at methods of streamlining out existing business, and work with our main investors and financiers to develop improved laboratory operations. This often involves discussing product formulations with existing and potentially new formulators. Some days involve participating in board meetings, preparing quarterly financial reports, speaking on company conference calls and representatives’ podcasts, and speaking with doctors interested in CBD.

What has been your biggest lesson about working in cannabis, and in business in general?

When it comes to business in general, extraordinary patience can be a virtue. As far as cannabis goes – never take anything for granted

What do you see as your biggest opportunity?
To revolutionize neurological medicine, educate doctors as well as lay people about the therapeutic benefits of cannabis, change the way we think about cannabis, develop a national dialogue regarding cannabis, and – on a personal note – to retire someday.

Do you have any thoughts or concerns about Sean Spicer’s statements indicating the Administration’s intention to crack down on recreational cannabis?
None at all, I consider it a smokescreen to distract from other happenings.

What sets you apart to make you a potential leader in cannabis?
My in-depth knowledge of the science and research, and that we are actually doing it. We currently have two divisions in pharma development, and are the first to do so.

What is the most frustrating aspect of the cannabis industry today?
Everyone wants to make a quick nickel instead of a slow dollar

What would you say to those who are considering investing in your company?
We are a diversified portfolio company with 4 divisions in nutraceutical sales. We have two investment companies in pharmaceutical development. The trends toward legalization of cannabis are unmistakable. The international acceptance of cannabis and CBD products is growing. The ability to grow hemp here in the US is a compelling business opportunity. With legalization, our company plans to enter into the THC space. We would potentially have multiple sources of revenue in the future. There is excellent investor interest in the space at this time.

What are the biggest challenges of being a publicly offered cannabis company?
The reporting requirements are staggering in terms of manpower, hours, and expense. It’s also a challenge to separate inside information from public information.

What advice would you give to anyone looking to get into the cannabis space?
This is potentially one of the greatest growth industries in America. The magnitude and impact of this could be bigger than anything previously seen. We can move toward a sustainable, renewable economy with jobs for all.

What are your biggest tips for branding cannabis?
Separate yourself from the crowd through innovation.

Do you see any big changes coming in the future of cannabis?
There will be more cannabinoids, and more acceptance of botanical cannabis. The US will follow Canada in allowing licensed producers. The US will also follow Canada in terms of full recreational legalization.

Do you consume cannabis? And if so, what's your favorite way to consume?
Yes, at least 50 mg of CBD daily. In the morning I take RSHO Blue. Through the day, Revive Pro. At night, RSHO Green. And I apply a topical salve daily. Occasionally I’ll enjoy a THC edible.

martedì 7 marzo 2017

Cannabis Science Inc (OTCMKTS:CBIS) To Attend Global Health Catalyst Summit At Harvard Medical School

Cannabis Science Inc (OTCMKTS:CBIS) has announced that it would be represented by its CEO, Raymond C. Dabney, at the Global Health Catalyst Summit, due to be held at the Harvard Medical School, on April 28-30, 2017. The company stated that Mr. Dabney would be a keynote speaker, at the summit and would also be a part of the panel. Added to this, the CMO of CBIS, Allen Herman, has also been invited to the summit, to co-chair a special session at the summit.
It should be noted here that Cannabis Science and the Harvard Medical School have a close working relationship. Mr. Dabney and Mr. Herman, have previously visited the school and delivered presentations about the rapidly developing medical cannabis industry. Further details from the company have revealed that Mr. Dabney has been asked to be a keynote speaker and panelist for a special session on “Cannabis Science Versus Cancer and Other Malignancies.”
In addition to this, Mr. Dabney plans to use the summit as a platform for providing an overview of the company, its drug development programs and the ongoing collaborative research agreement between the school and the company. CBIS is viewing the summit as an opportunity to discuss some of its cutting edge research, with the top minds in the medicinal industry. Moreover, the company also plans to establish partnerships, with institutions, present at the conference.
Mr. Dabney expressed his excitement about the potential partnership with the Dana-Farber Research Center, at Harvard Medical School. He claimed that his meeting with Wilfred Ngwa, the director of global health catalyst, at the center, had led to the immediate realization of potential synergies, in cancer research. The two had first met in September 2016, at the annual Constituency For Africa summit and went on to develop a research partnership in later months.
Cannabis Science Inc (OTCMKTS:CBIS) completed the March 3 trading session with a gain of 3.87% in terms of its share value, to close at $0.094 per share. The stock had a trade volume of 34.72 million, during the session.